🇺🇸 FDA
Pipeline program

Ultravist 370 mg/ml soluzione iniettabile

IEO 960

Phase 2 small_molecule active

Quick answer

Ultravist 370 mg/ml soluzione iniettabile for Patients with breast lesions undergoing further examination is a Phase 2 program (small_molecule) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).

Program details

Company
Istituto Gentili S.r.l.
Indication
Patients with breast lesions undergoing further examination
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials